Additionally, CALR is clinically associated with high survival rates in colorectal cancer patients (Arai & Xiao, 2020), indicating that a combination of NTMT1 protein degradation drugs and immune checkpoint therapy may improve the efficacy of tumor treatment. Here, NTMT1 is linked to colorectal cancer.